Archive by category | Uncategorized

Guidelines for algorithms and software at Nature Biotechnology

Guidelines for algorithms and software at Nature Biotechnology

Nature Biotechnology outlined its recommendations for material sharing and reporting for algorithms and software in a April 2015 Editorial. On this page, the editors provide more detailed information for authors submitting manuscripts containing unpublished algorithms and software.  Read more

The Aging of BIO International Convention

The Aging of BIO International Convention

Before BIO CEO Jim Greenwood interviewed broadcast journalist Tom Brokaw during Tuesday’s plenary lunch, Philadelphia Mayor Michael Nutter took the podium. This is standard fare for a BIO convention: the hosting mayor gets a chance to brag a little bit about their city, and thank BIO for bringing all these people to local hotels and restaurants.  Read more

Encouraging Pharma in Brazil 2: Shifting Paradigms

Encouraging Pharma in Brazil 2: Shifting Paradigms

Slightly more than two years ago I made a contribution to Trade Secrets on the very topic I’m about to again write about. In fact I have been dealing with this subject over the last five years. I devoted a whole chapter of an eBook I published with Bentham E Books last year: Opportunities and Limitation for Biotechnology Innovation in Brazil. Why is this issue so important?  Read more

China’s Biotech Future

China's Biotech Future

Continuing our interview series with life sciences venture capitalists to accompany a study on venture capital in emerging markets published in the March 7th, 2013, issue of Nature Biotechnology, we return to China. Our third interview is with a venture capitalist, who wishes to remain anonymous, from the one of the most prolific early-stage life sciences investors in China (14 innovation-focused investments to date). Previous posts are here and here.  Read more

Wellspring — the health of private biotech

Wellspring -- the health of private biotech

For nonsubscribers, we’ve made our annual feature on the health of the private biotech space freely available.  Much of the data are supplied by Dow Jones VentureSource, tailored to our requests and definitions of biotech, and highlight what many already know: venture capital funding for early stage innnovative companies continues to dwindle. The article also investigates start-up activity from universities, exits and more.  Go here for the PDF, and here for HTML version.  Read more

New Drug for an Age-Old Disease

New Drug for an Age-Old Disease

At the end of 2012, the US Food & Drug Administration approved Sirturo, also known as bedaquiline as a viable treatment option for patients with drug-resistant strains of tuberculosis.  This was an important announcement for the TB drugs community as the last drug with a new mechanism of action approved for TB was rifampicin in 1963. Innovation in tuberculosis drugs and antibiotics in general, since then, has languished.  Read more